Retinitis pigmentosa (RP) is a heterogeneous group of hereditary diseases characterized by
progressive degeneration of retinal photoreceptors leading to progressive visual decline. It …

There are promising new strategies for AMD. Many of the potential new treatments are in or
have recently completed phase 2 or phase 3 clinical trials with promising results thus far …

Ocular drug delivery is one of the most challenging endeavors among the various available
drug delivery systems. Despite having suitable drugs for the treatment of ophthalmic …

A retinal prosthesis, also known as a bionic eye, is a device that can be implanted to partially
restore vision in patients with retinal diseases that have resulted in the loss of …

Background: The development and use of human embryonic stem cells (hESCs) in
regenerative medicine have been revolutionary, offering significant advancements in …

Purpose: To report 1-year follow-up of a phase 1/2a clinical trial testing a composite
subretinal implant having polarized human embryonic stem cell (hESC)-derived retinal …

Cell-based therapies face challenges, including poor cell survival, immune rejection, and
integration into pathologic tissue. We conducted an open-label phase 1/2a clinical trial to …

Purpose To report long-term results from a phase 1/2a clinical trial assessment of a scaffold-
based human embryonic stem cell-derived retinal pigmented epithelium (RPE) implant in …

Retinal pigment epithelial (RPE) cells have several functions, including support of the neural
retina and choroid in the eye and immunosuppression. Cultured human RPE cells directly …

Retinal pigment epithelium (RPE) cells grown on a scaffold, an RPE patch, have potential to
ameliorate visual impairment in a limited number of retinal degenerative conditions. This …